Ultragenyx Q2 revenue $147M (+36% YoY), raises 2024 guidance; key FDA agreements advance pipeline

Ultragenyx Pharmaceutical Inc.

2024-Q2 EPS reported -$3.54 revenue$255,859,000

Q2 total revenue $147M (Crysvita $114M, Dojolvi $19M); net loss narrows to $132M from $160M.
2024 revenue guidance raised to $530-550M (prev $500-530M); Crysvita expected towards upper end of $375-400M.
Cash $874M after June equity offering of $381M net; 2024 operating cash use guided below $400M.
FDA agrees CSF heparan sulfate as surrogate endpoint for UX111 Sanfilippo accelerated approval; BLA filing late-2024/early-2025.
Positive Phase 3 data for DTX401 in GSDIa (41.3% reduction in cornstarch, p<0.0001); Phase 2/3 OI setrusumab shows 67% fracture reduction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.